Pharma News

1 October 2025

AbbVie expands Biologics Manufacturing and R&D Presence in the U.S., invests USD 70 mn

AbbVie announced the start of construction of a USD 70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass., which serves as a center of excellence for biologics research and development and manufacturing. This expansion is part of the company's previously announced commitment to invest more than USD 10 billion of capital in the U.S. to broadly support innovation and expand critical biologics manufacturing capabilities and capacity.

1 October 2025

Lupin launches Rivaroxaban for oral suspension in the United States

Lupin launches Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States, which is bioequivalent to Xarelto of Janssen Pharmaceuticals, Inc.

1 October 2025

Pfizer to cut prices up to 85% after signing pact with U.S. Government

Pfizer signs pact with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening Americas role as the global leader in biopharmaceutical innovation.

30 September 2025

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab)

Amneal Pharmaceuticals, Inc. announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a proposed biosimilar to XOLAIR

29 September 2025

New Drug Candidate Blocks Lung Cancer Growth Without Harming Healthy Cells

Lung cancer remains one of the deadliest cancers worldwide, with survival rates stubbornly low despite advances in surgery, chemotherapy, and immunotherapy. But a new discovery may change the way doctors approach treatment.

26 September 2025

Alkem launches Pertuza, a pertuzumab biosimilar, in India

Alkem Laboratories Ltd. announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer.

26 September 2025

Glenmark Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), today announced that it has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC).

26 September 2025

Lupin Receives Tentative Approval from USFDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets

Global pharma major Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg. This product would be manufactured at Lupin’s Nagpur facility in India.

26 September 2025

Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs

The revolutionary HIV prevention tool, injectable lenacapavir, will be available at a cost of USD 40 a year in 120 low- and middle-income countries starting in 2027, under a new partnership announced today between Dr. Reddy’s Laboratories and Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI

26 September 2025

Systemically injectable therapy could prevent heart failure after a heart attack

Scientists at Northwestern University and University of California San Diego have developed a new, potent injectable therapy that can protect the heart from damage after a heart attack.

Search

AbbVie expands Biologics Manufacturing and R&D Presence in the U.S., invests USD 70 mn

RECOMMENDED POSTS

Subscribe with us

Jobs by Category